Free Trial
Your Portfolio Deserves Better! MarketBeat All Access for Just $149
Upgrade Now
Claim MarketBeat All Access Sale Promotion
NASDAQ:NAKA

KindlyMD 5/8/2025 Earnings Report

KindlyMD logo
$6.37 -0.25 (-3.83%)
As of 01:21 PM Eastern

KindlyMD EPS Results

Actual EPS
-$0.17
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

KindlyMD Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

KindlyMD Announcement Details

Quarter
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

KindlyMD Earnings Headlines

Nakamoto Announces Expansion of Board of Directors
The S-1 just dropped. 22 days left.
The SpaceX S-1 is now public - $18.7 billion in revenue, a $75 billion raise, and a June 12 Nasdaq listing confirmed. Goldman, Morgan Stanley, and 19 other banks have already carved up the allocation. But buried in those 277 pages is a detail most investors will miss. One small, publicly traded company is so critical to SpaceX's infrastructure that Musk can't scale without it - and the S-1 just confirmed it.tc pixel
See More KindlyMD Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like KindlyMD? Sign up for Earnings360's daily newsletter to receive timely earnings updates on KindlyMD and other key companies, straight to your email.

About KindlyMD

Kindly MD, Inc. (“KindlyMD (NASDAQ:NAKA)” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis. The Company offers evaluation and management, including, but not limited to chronic pain, functional medicine, cognitive behavioral therapy, trauma and addiction therapy, recovery support services, overdose education efforts, peer support, limited urgent care, preventative medicine, medically managed weight loss, and hormone therapy. Through its focus on an embedded model of prescriber and therapist teams, KindlyMD develops patient-specific care programs with a specific mission to reduce opioid use in the patient population while successfully treating patients with effective and evidence-based non-opioid alternatives in close conjunction with behavioral therapy. Beyond its treatment of patients, KindlyMD collects data focused on why and how patients turn to alternative treatments to reduce prescription medication use and addiction. The Company captures all relevant datapoints to assist and appropriately treat each individual patient. This also results in valuable data for the Company and the Company’s investors. We strive to become a source for evidence-based guidelines, data, treatment models, and education in the fight against the opioid crisis in America. Business Revenue Streams We currently earn revenue through (i) patient care services related to medical evaluation and treatment and (ii) product retail sales. Our forecasted plan is to operate across various revenue streams: (i) medical evaluation and treatment visits reimbursed by Medicare, Medicaid, and commercial insurance payers as well as self-pay services, (ii) data collection and research, (iii) education partnerships, (iv) service affiliate agreements, and (v) retail sales. Our principal executive offices are located at 5097 S 900 E, Suite 100 Salt Lake City, UT.

View KindlyMD Profile